Diverse neurological effects linked to anti-PD-1 therapy

Diverse neurological effects linked to anti-PD-1 therapy

(HealthDay)—Neurological complications associated with anti-programmed death 1 (PD-1) antibody treatment have a diverse phenotype, according to a study published online Sept. 5 in JAMA Neurology.

Justin C. Kao, M.B.Ch.B., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a involving patients with development of neurological symptoms within 12 months of receiving anti-PD-1 therapy.

The researchers found that 2.9 percent of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of . Seven of these patients received pembrolizumab and three nivolumab. Neurological complications occurred after a median of 5.5 anti-PD-1 inhibitor cycles. Myopathy, varied neuropathies, cerebellar ataxia, autoimmune retinopathy, bilateral internuclear ophthalmoplegia, and headache were reported complications. Reported were axonal and demyelinating polyradiculoneuropathies, length-dependent neuropathies, and asymmetric vasculitic neuropathy.

"Neurological adverse events associated with anti-PD-1 therapy have a diverse phenotype, with more frequent neuromuscular complications," the authors write. "Prompt recognition and discontinuation of anti-PD-1 is recommended. In some cases, immune rescue treatment may be required."

One author disclosed financial ties to the pharmaceutical industry.


Explore further

Melanoma therapy tied to cutaneous adverse events

More information: Abstract/Full Text
Editorial
Journal information: Archives of Neurology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Diverse neurological effects linked to anti-PD-1 therapy (2017, September 11) retrieved 5 August 2021 from https://medicalxpress.com/news/2017-09-diverse-neurological-effects-linked-anti-pd-.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments